Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Aciclovir/etanercept/hydroxychloroquine

Aciclovir/etanercept/hydroxychloroquine Reactions 1704, p14 - 2 Jun 2018 Aciclovir/ etanercept/hydroxychloroquine Disseminated cutaneous herpes zoster and acute renal failure: case report A 75-year-old woman developed disseminated cutaneous herpes zoster infection during treatment with etanercept and hydroxychloroquine for rheumatoid arthritis. Additionally, she developed acute renal failure during treatment with aciclovir for disseminated cutaneous herpes zoster infection [dosages and durations of treatments to reactions onsets not stated; not all routes stated]. The woman, who was receiving treatment with etanercept and hydroxychloroquine for rheumatoid arthritis, presented to the emergency department due to generalised body pain and widespread rash. She reported that the skin lesions initially erupting on her buttocks and scalp and then spread to her back and chest. On examination, she demonstrated a large group of erythematous vesicles following the S1 dermatome and numerous pox-like lesions scattered throughout the buccal mucosa, palate, scalp, face, chest and back. Due to her immunocompromised state and widespread vesicular lesions, her clinical presentation was concerning for disseminated cutaneous herpes zoster. The woman was hospitalised for IV antiviral therapy with aciclovir and both hydroxychloroquine and etanercept were discontinued. She responded well to aciclovir therapy. However, she developed acute renal failure secondary to aciclovir, with creatinine level of 2.6 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Aciclovir/etanercept/hydroxychloroquine

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Aciclovir/etanercept/hydroxychloroquine

Abstract

Reactions 1704, p14 - 2 Jun 2018 Aciclovir/ etanercept/hydroxychloroquine Disseminated cutaneous herpes zoster and acute renal failure: case report A 75-year-old woman developed disseminated cutaneous herpes zoster infection during treatment with etanercept and hydroxychloroquine for rheumatoid arthritis. Additionally, she developed acute renal failure during treatment with aciclovir for disseminated cutaneous herpes zoster infection [dosages and durations of treatments to reactions onsets...
Loading next page...
 
/lp/springer_journal/aciclovir-etanercept-hydroxychloroquine-o3UM1H8zeg

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46657-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p14 - 2 Jun 2018 Aciclovir/ etanercept/hydroxychloroquine Disseminated cutaneous herpes zoster and acute renal failure: case report A 75-year-old woman developed disseminated cutaneous herpes zoster infection during treatment with etanercept and hydroxychloroquine for rheumatoid arthritis. Additionally, she developed acute renal failure during treatment with aciclovir for disseminated cutaneous herpes zoster infection [dosages and durations of treatments to reactions onsets not stated; not all routes stated]. The woman, who was receiving treatment with etanercept and hydroxychloroquine for rheumatoid arthritis, presented to the emergency department due to generalised body pain and widespread rash. She reported that the skin lesions initially erupting on her buttocks and scalp and then spread to her back and chest. On examination, she demonstrated a large group of erythematous vesicles following the S1 dermatome and numerous pox-like lesions scattered throughout the buccal mucosa, palate, scalp, face, chest and back. Due to her immunocompromised state and widespread vesicular lesions, her clinical presentation was concerning for disseminated cutaneous herpes zoster. The woman was hospitalised for IV antiviral therapy with aciclovir and both hydroxychloroquine and etanercept were discontinued. She responded well to aciclovir therapy. However, she developed acute renal failure secondary to aciclovir, with creatinine level of 2.6

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.